Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

The US Food and Drug Administration (FDA) has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer ...

Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...

French pharma major Sanofi’s consumer healthcare business, Opella, has announced that the US Food and Drug Administration ...

Opella reaches study milestone for CialisParis, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and ...

Sanofi’s (NASDAQ ... use trial (AUT), which it has planned to support a potential switch of Cialis tablets from a prescription-only medicine to an over-the-counter product.

(RTTNews) - Sanofi's Consumer Healthcare division ... Cialis (tadalafil) in the US is currently only available with a prescription. Cialis is a tablet taken to treat erectile dysfunction (ED ...

As the only available tablet via prescription in the country, Cialis is used to treat ED, benign prostatic hyperplasia symptoms, and both conditions simultaneously. Earlier this month, Sanofi ...

Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis ...

Opella, Sanofi’s Consumer Healthcare business ... Cialis (tadalafil) in the US is currently only available with a prescription. Cialis is a tablet taken to treat erectile dysfunction (ED ...